What are the implications of adjuvant therapy data on biomarker evaluation?
touchMDT for touchONCOLOGY
Listen to a medical oncologist and a pathologist discuss the benefits of biomarker testing in early and locally advanced NSCLC.
The multidisciplinary team
Medical oncologist: Dr David Planchard, France
Molecular pathologist: Prof. Albrecht Stenzinger, Germany
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from AstraZeneca. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/evolving-role-mdt-early-nsclc/
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.